Recludix Pharma, a leader in the discovery of inhibitors of challenging targets for inflammatory disease, today announced ...

In a recent article titled “ Big Pharma says ‘Thanks, but No Thanks’ to their own HEOR groups, ” Professor Scott Ramsey from ...

Mr. Shinichi Tamura, Mr. Tomohiro Tohyama and Mr. Kuniaki Kaga to retire from the Board of Directors ...

Chemical companies in the US and Europe began exiting the pharmaceutical industry in the mid-1990s, when the British firm ICI ...

“Companies are realizing that investing stateside can provide more control and resilience to the drug supply chain,” says Dymowski. She cites political tensions, import and export disruptions, and ...

Astellas has changed its management structure, establishing new top management positions and making personnel changes. The goal of the change is to promote drug discovery activities swiftly and ...

Not satisfied with simply changing personnel, Japanese drugmaker Astellas has announced a new management structure, effective ...

Portfolio Receipts of $742 million in Q4 2024 and $2,801 million for FY 2024Royalty Receipts growth of 12% in Q4 2024 and 13% for FY 2024 Net ...

Union Minister of State for Health and Family Welfare, Anupriya Patel, delivered the keynote address at the 15th ...

Indian Cephalexin Market Indian Cephalexin Market Dublin, Jan. 31, 2025 (GLOBE NEWSWIRE) -- The "India Cephalexin Market, By ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the following changes to its management structure effective April 1, 2025.

Novartis AG (NYSE:NVS), a global healthcare powerhouse with a market capitalization of $208.27 billion, has recently transformed into a pure-play pharmaceutical company, sharpening its focus on its ...